251 related articles for article (PubMed ID: 33832365)
1. Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation.
Chung C
J Oncol Pharm Pract; 2022 Jun; 28(4):850-869. PubMed ID: 33832365
[TBL] [Abstract][Full Text] [Related]
2. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
3. KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician.
Afrăsânie VA; Marinca MV; Alexa-Stratulat T; Gafton B; Păduraru M; Adavidoaiei AM; Miron L; Rusu C
Radiol Oncol; 2019 Sep; 53(3):265-274. PubMed ID: 31553708
[TBL] [Abstract][Full Text] [Related]
4. BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
Cohen R; Cervera P; Svrcek M; Pellat A; Dreyer C; de Gramont A; André T
Curr Treat Options Oncol; 2017 Feb; 18(2):9. PubMed ID: 28214977
[TBL] [Abstract][Full Text] [Related]
5. Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update.
Baraibar I; Ros J; Mulet N; Salvà F; Argilés G; Martini G; Cuadra JL; Sardo E; Ciardiello D; Tabernero J; Élez E
Expert Rev Mol Diagn; 2020 Jul; 20(7):653-664. PubMed ID: 32552041
[TBL] [Abstract][Full Text] [Related]
6. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer.
Kloth M; Ruesseler V; Engel C; Koenig K; Peifer M; Mariotti E; Kuenstlinger H; Florin A; Rommerscheidt-Fuss U; Koitzsch U; Wodtke C; Ueckeroth F; Holzapfel S; Aretz S; Propping P; Loeffler M; Merkelbach-Bruse S; Odenthal M; Friedrichs N; Heukamp LC; Zander T; Buettner R
Gut; 2016 Aug; 65(8):1296-305. PubMed ID: 26001389
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.
Cushman-Vokoun AM; Stover DG; Zhao Z; Koehler EA; Berlin JD; Vnencak-Jones CL
Clin Colorectal Cancer; 2013 Sep; 12(3):168-78. PubMed ID: 23773459
[TBL] [Abstract][Full Text] [Related]
8. Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.
Cocco E; Benhamida J; Middha S; Zehir A; Mullaney K; Shia J; Yaeger R; Zhang L; Wong D; Villafania L; Nafa K; Scaltriti M; Drilon A; Saltz L; Schram AM; Stadler ZK; Hyman DM; Benayed R; Ladanyi M; Hechtman JF
Cancer Res; 2019 Mar; 79(6):1047-1053. PubMed ID: 30643016
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients.
Zlobec I; Molinari F; Kovac M; Bihl MP; Altermatt HJ; Diebold J; Frick H; Germer M; Horcic M; Montani M; Singer G; Yurtsever H; Zettl A; Terracciano L; Mazzucchelli L; Saletti P; Frattini M; Heinimann K; Lugli A
Br J Cancer; 2010 Jan; 102(1):151-61. PubMed ID: 19935791
[TBL] [Abstract][Full Text] [Related]
10. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
11. Fusion Kinases Identified by Genomic Analyses of Sporadic Microsatellite Instability-High Colorectal Cancers.
Sato K; Kawazu M; Yamamoto Y; Ueno T; Kojima S; Nagae G; Abe H; Soda M; Oga T; Kohsaka S; Sai E; Yamashita Y; Iinuma H; Fukayama M; Aburatani H; Watanabe T; Mano H
Clin Cancer Res; 2019 Jan; 25(1):378-389. PubMed ID: 30279230
[TBL] [Abstract][Full Text] [Related]
12. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
13. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
[TBL] [Abstract][Full Text] [Related]
15. Molecular Profiling in Metastatic Colorectal Cancer.
Armstrong SA; Malley R; Weinberg BA
Oncology (Williston Park); 2020 Sep; 34(9):352-355. PubMed ID: 32965665
[TBL] [Abstract][Full Text] [Related]
16. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
[TBL] [Abstract][Full Text] [Related]
17. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.
Zlobec I; Kovac M; Erzberger P; Molinari F; Bihl MP; Rufle A; Foerster A; Frattini M; Terracciano L; Heinimann K; Lugli A
Int J Cancer; 2010 Dec; 127(11):2569-75. PubMed ID: 20162668
[TBL] [Abstract][Full Text] [Related]
18. Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
Fujiyoshi K; Yamamoto G; Takenoya T; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
Anticancer Res; 2017 Jan; 37(1):239-247. PubMed ID: 28011498
[TBL] [Abstract][Full Text] [Related]
19. Lynch syndrome-associated colorectal carcinoma: frequent involvement of the left colon and rectum and late-onset presentation supports a universal screening approach.
Hartman DJ; Brand RE; Hu H; Bahary N; Dudley B; Chiosea SI; Nikiforova MN; Pai RK
Hum Pathol; 2013 Nov; 44(11):2518-28. PubMed ID: 24034859
[TBL] [Abstract][Full Text] [Related]
20. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
Demurtas L; Puzzoni M; Giampieri R; Ziranu P; Pusceddu V; Mandolesi A; Cremolini C; Masi G; Gelsomino F; Antoniotti C; Loretelli C; Meriggi F; Zaniboni A; Falcone A; Cascinu S; Scartozzi M
Br J Cancer; 2017 Jul; 117(3):315-321. PubMed ID: 28632725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]